Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
2.9Last Year’s EPS
3.67Same Quarter Last Year
Moderate Buy
Based on 31 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -0.12%
|Next Earnings Date:Jul 23, 2025
Earnings Call Sentiment|Positive
The earnings call indicates a positive outlook for Biogen, with strong growth in new product segments and significant pipeline progress. However, challenges remain in the form of declining MS revenue and potential tariff impacts.Company Guidance
In the recent Biogen earnings call, the company provided guidance for the fiscal year 2025, emphasizing the evolution of its product portfolio and financial outlook. Biogen anticipates a mid-single-digit decline in total revenue for 2025, primarily due to increased competition and expected declines in its MS business. Despite these challenges, the company projects growth in its launch products, which together generated approximately $200 million in revenue in Q1, reflecting a 22% increase quarter-over-quarter. The company also highlighted its strong balance sheet, with $2.6 billion in cash and $3.7 billion in net debt, enabling continued investment in both internal and external growth opportunities. Biogen's full-year non-GAAP diluted earnings per share guidance has been updated to $14.50-$15.50, reflecting the impact of a $165 million upfront payment for the Stoke transaction and a $0.20 tailwind from foreign exchange impacts. Additionally, Biogen indicated that even if the recently announced U.S. tariffs were implemented, they would not materially affect the company's 2025 financial outlook, largely due to its U.S.-based manufacturing and global inventory positions.Strong Start to the Year
Biogen reported a strong first quarter with a significant shift in its revenue composition. The new product portfolio, including ZURZUVAE, LEQEMBI, and VUMERITY, now represents about 45% of the company's product revenue.
LEQEMBI Commercial Success
LEQEMBI achieved $96 million in revenue. The product has received marketing authorization in the EU, reinforcing its efficacy, safety profile, and importance.
SKYCLARYS Growth
SKYCLARYS generated worldwide sales of $124 million, marking a 59% year-over-year increase and 21% quarter-over-quarter growth. The product has been launched in 26 markets.
Pipeline Progress
Biogen initiated the Phase 3 TRANSCEND study for felzartamab in AMR and received FDA Fast Track designation for their ASO targeting BIIB080 in Alzheimer's before even reading out Phase 2.
---
BIIB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BIIB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 01, 2025 | $121.08 | $120.93 | -0.12% |
| Feb 12, 2025 | $139.39 | $133.43 | -4.28% |
| Oct 30, 2024 | $183.47 | $181.18 | -1.25% |
| Aug 01, 2024 | $213.20 | $210.70 | -1.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biogen (BIIB) report earnings?
Biogen (BIIB) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Biogen (BIIB) earnings time?
Biogen (BIIB) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIIB EPS forecast?
BIIB EPS forecast for the fiscal quarter 2025 (Q1) is 2.9.
---
